Dr. Carlos Garcia-Echeverria is an accomplished drug discovery scientist and executive, focused on bringing new therapies to patients in need.
Carlos has provided scientific leadership to drug discovery and early clinical development teams across different modalities and diseases most recently at Sanofi as Chief Operating Officer of Research and at Novartis as Executive Director, Oncology Drug Discovery Head. Carlos has also broad experience in managing research partnerships. His research accomplishments are documented by 190 peer-reviewed articles, book chapters and review papers, and 45 granted patents.
Carlos holds a PhD in organic chemistry from the University of Barcelona and received the Leonidas Zerwas Award from the European Peptide Society in recognition of his outstanding contributions to peptide science. Carlos is a member of the Scientific Advisory Board of several biotech companies.
Daniel Hoey is an industry leader in pharmaceutical product development, manufacturing operations and supply chain management with over 30 years of experience in the industry. Prior to joining EQRx, Dan led global supply chain operations at Teva, where he drove the transformation of one of the industry’s largest and most complex global pharmaceutical supply chains focused on patient-centric healthcare solutions.
Previously, Dan held senior leadership roles at Teva API and Biologics, as well as Merck, where he spent 27 years in technical operations, commercialization, strategy development and contract manufacturing. Dan is certified in application of lean manufacturing and six-sigma process improvement in pharmaceutical operations.
Dan holds a Bachelor of Science in Chemical Engineering from Michigan State University.
Dina Ciarimboli is an experienced legal professional with more than 25 years of experience in the life sciences industry.
Most recently, she served as the chief legal officer at Thrive Earlier Detection Corp. and as a member of the senior leadership team, where she was involved from inception through the sale of the company. Prior to that, she served as the general counsel at Third Rock Ventures for more than 7 years where she was involved in creating, launching and building a wide variety of biotech companies.
She received her J.D. from Boston College Law School and her B.S. in accounting and philosophy from Boston College.
Rona Anhalt has a proven track record of scaling organizations for growth and building high performing teams in life sciences. With more than 20 years of experience, she previously led human resource functions at Celgene and Novartis, aligning people and talent strategies to drive business performance and results.
Rona started her career in banking and technology before moving into the life sciences industry. She holds an MBA in finance from New York University, as well as a bachelor’s in accounting and economics from Queens College.
Dr. Miller is one of the world’s experts in lung cancer and clinical trial design and interpretation. His work was critical to identification of EGFR sensitizing and resistance mutations.
Among his many accolades, Dr. Miller received the American Cancer Society Clinical Oncology Career Development Award and is a fellow of the American College of Physicians.
Dr. Miller spent nearly 20 years as an attending physician focused in thoracic oncology at Memorial Sloan Kettering Cancer Center. He has also served as Chief Medical Resident at Thomas Jefferson University Hospital. Most recently, he served as Chief Medical Officer at Foundation Medicine.